NEW YORK, Dec. 18 — IBM will become the preferred technology partner for structural proteomics firm GeneFormatics, the companies said on Tuesday.
According to the agreement, the computer giant will provide hardware, software, and services to support GeneFormatics, and has staked a claim in the company's third round of equity financing, originally announced in October.
Financial details of the deal, including IBM's equity investment, were not disclosed.
GeneFormatics' core business is a proprietary "function first" approach to protein analysis, an effort designed to determine protein function prior to high-resolution 3-D structure analysis. GeneFormatics is betting that IBM's IT technology will help it develop this process.
The system IBM will provide will include a group of Linux-based eServer xSeries 330 systems, its Enterprise Storage Server, and a DB2 Universal database. GeneFormatics also plans to add IBM's DiscoveryLink data integration software to help organize and synthesize proteomic information.
GeneFormatics, headquartered in San Diego, Calif., had raised $22 million in its third round of financing.